MONECO Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.11M | Buy |
170,546
+112,908
| +196% | +$2.95M | 0.25% | 82 |
|
|
2026
Q1 | $1.62M | Buy |
57,638
+2,931
| +5% | +$78K | 0.13% | 157 |
|
|
2025
Q4 | $1.36M | Buy |
54,707
+6,188
| +13% | +$156K | 0.11% | 174 |
|
|
2025
Q3 | $1.24M | Buy |
48,519
+13,515
| +39% | +$334K | 0.1% | 177 |
|
|
2025
Q2 | $849K | Buy |
35,004
+7,969
| +29% | +$186K | 0.08% | 210 |
|
|
2025
Q1 | $685K | Buy |
27,035
+3,198
| +13% | +$83.7K | 0.07% | 225 |
|
|
2024
Q4 | $632K | Buy |
23,837
+81
| +0.3% | +$2.2K | 0.07% | 242 |
|
|
2024
Q3 | $687K | Sell |
23,756
-6,788
| -22% | -$198K | 0.09% | 200 |
|
|
2024
Q2 | $855K | Sell |
30,544
-852
| -3% | -$23.5K | 0.13% | 163 |
|
|
2024
Q1 | $871K | Buy |
31,396
+1,149
| +4% | +$31.9K | 0.14% | 167 |
|
|
2023
Q4 | $871K | Buy |
30,247
+7,862
| +35% | +$238K | 0.17% | 151 |
|
|
2023
Q3 | $742K | Buy |
22,385
+1,705
| +8% | +$60.3K | 0.2% | 123 |
|
|
2023
Q2 | $759K | Sell |
20,680
-343
| -2% | -$13.4K | 0.21% | 122 |
|
|
2023
Q1 | $858K | Buy |
21,023
+3,024
| +17% | +$131K | 0.25% | 101 |
|
|
2022
Q4 | $922K | Buy |
17,999
+406
| +2% | +$19.5K | 0.33% | 78 |
|
|
2022
Q3 | $770K | Buy |
17,593
+76
| +0.4% | +$3.69K | 0.31% | 82 |
|
|
2022
Q2 | $918K | Buy |
17,517
+3,083
| +21% | +$157K | 0.36% | 73 |
|
|
2022
Q1 | $747K | Sell |
14,434
-178
| -1% | -$9.24K | 0.27% | 84 |
|
|
2021
Q4 | $780K | Buy |
14,612
+871
| +6% | +$43.2K | 0.29% | 83 |
|
|
2021
Q3 | $591K | Buy |
13,741
+347
| +3% | +$15.4K | 0.23% | 98 |
|
|
2021
Q2 | $525K | Buy |
13,394
+643
| +5% | +$25K | 0.24% | 99 |
|
|
2021
Q1 | $462K | Sell |
12,751
-360
| -3% | -$12.8K | 0.22% | 106 |
|
|
2020
Q4 | $483K | Buy |
13,111
+1,758
| +15% | +$64.5K | 0.27% | 85 |
|
|
2020
Q3 | $395K | Buy |
11,353
+1,563
| +16% | +$54.8K | 0.25% | 89 |
|
|
2020
Q2 | $304K | Buy |
9,790
+438
| +5% | +$14.9K | 0.24% | 99 |
|
|
2020
Q1 | $290K | Buy |
9,352
+1,367
| +17% | +$46.6K | 0.3% | 84 |
|
|
2019
Q4 | $307K | Buy |
7,985
+592
| +8% | +$21.1K | 0.22% | 101 |
|
|
2019
Q3 | $252K | Sell |
7,393
-3
| -0% | -$109 | 0.2% | 108 |
|
|
2019
Q2 | $304K | Sell |
7,396
-211
| -3% | -$8.38K | 0.24% | 91 |
|
|
2019
Q1 | $307K | Buy |
7,607
+197
| +3% | +$7.89K | 0.25% | 94 |
|
|
2018
Q4 | $307K | Buy |
+7,410
| New | +$308K | 0.36% | 61 |
|
Other funds holding PFE
MONECO Advisors's PFE Position: Q2 2026 in Review
MONECO Advisors increased its Pfizer (PFE) stake by 196% in Q2 2026, buying an estimated $2.95M and bringing the position to 170,546 shares worth $4.11M. The position accounts for 0.25% of the portfolio, ranked #82.
MONECO Advisors first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- MONECO Advisors held 170,546 shares of Pfizer worth $4.11M as of Q2 2026.
- MONECO Advisors bought 112,908 Pfizer shares in Q2 2026, an estimated $2.95M.
- Pfizer made up 0.25% of MONECO Advisors's portfolio in Q2 2026, its #82 holding.
- MONECO Advisors first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on MONECO Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.